FLT3 and acute myeloid leukemia: In agreement with these findings, Ueno et al. [69] recently demonstrated that simultaneous treatment with a FLT3 inhibitor (i.e., gilteritinib) and standard AML chemotherapy markedly enhanced chemotherapy response in FLT3-ITD mutant AML patient-derived xenografts.